Trial Profile
A phase III study of telaprevir in combination with VX 222, pegylated interferon alpha 2a, and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C, or patients who have relapsed after at least one course of treatment with pegylated interferon and ribavirin alone.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2011
Price :
$35
*
At a glance
- Drugs Interferon alpha-2a (Primary) ; Lomibuvir (Primary) ; Ribavirin (Primary) ; Telaprevir
- Indications Hepatitis C
- Focus Therapeutic Use
- 07 Nov 2011 New trial record